{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:50:35Z","timestamp":1758819035705,"version":"3.44.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ygyno.2020.11.035","type":"journal-article","created":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T01:00:05Z","timestamp":1607216405000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease"],"prefix":"10.1016","volume":"161","author":[{"given":"Jessica","family":"Jou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Charo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Yau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Saenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramez","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"McHale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jula","family":"Veerapong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Plaxe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratibha","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3 Suppl 4","key":"10.1016\/j.ygyno.2020.11.035_bb0005","first-page":"1","article-title":"Theoretical and experimental bases of intraperitoneal chemotherapy","volume":"12","author":"Dedrick","year":"1985","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.035_bb0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian Cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.035_bb0015","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2020.11.035_bb0020","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ygyno.2020.11.035_bb0025","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology\/gynecologic oncology group study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.11.035_bb0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: rationale and technique","volume":"2","author":"Gonz\u00e1lez-Moreno","year":"2010","journal-title":"World Journal of Gastrointestinal Oncology."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.035_bb0035","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/1471-2407-6-162","article-title":"Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations","volume":"6","author":"Pelz","year":"2006","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2020.11.035_bb0040","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","article-title":"Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence","volume":"7","author":"Ceelen","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.035_bb0045","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1245\/s10434-012-2784-6","article-title":"Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia","volume":"20","author":"Pelz","year":"2013","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.035_bb0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1470-2045(04)01425-1","article-title":"Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia","volume":"5","author":"Glehen","year":"2004","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.11.035_bb0055","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1245\/s10434-007-9701-4","article-title":"Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center","volume":"15","author":"Gusani","year":"2008","journal-title":"Ann. Surg. Oncol."},{"issue":"18_suppl","key":"10.1016\/j.ygyno.2020.11.035_bb0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","article-title":"A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7","volume":"36","author":"Quenet","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.ygyno.2020.11.035_bb0065","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2020.11.035_bb0070","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","article-title":"Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients","volume":"39","author":"Bakrin","year":"2013","journal-title":"Eur. J. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2020.11.035_bb0075","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/IGC.0b013e31824d836c","article-title":"Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer","volume":"22","author":"Ansaloni","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2020.11.035_bb0080","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2020.11.035_bb0085","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ejso.2015.08.172","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis","volume":"41","author":"Huo","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.11.035_bb0090","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.11.035_bb0095","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"issue":"6","key":"10.1016\/j.ygyno.2020.11.035_bb0100","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ejso.2016.03.015","article-title":"A new internet tool to report peritoneal malignancy extent. PeRitOneal MalIgnancy stage evaluation (PROMISE) application","volume":"42","author":"Villeneuve","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"author":"Cancer Institute N","key":"10.1016\/j.ygyno.2020.11.035_bb0105"},{"key":"10.1016\/j.ygyno.2020.11.035_bb0110","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer report from the fourth ovarian cancer consensus conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"year":"2020","series-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline","author":"Eisenhauer","key":"10.1016\/j.ygyno.2020.11.035_bb0115"},{"year":"2010","series-title":"Optimal treatment for relapsing ovarian cancer. Educational Book of the 35th ESMO Congress Milan, Italy 8\u201312 October 2010","author":"Ledermann","key":"10.1016\/j.ygyno.2020.11.035_bb0120"},{"year":"2017","series-title":"Society Position Statements\/White Papers An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.","author":"Salani","key":"10.1016\/j.ygyno.2020.11.035_bb0125"},{"issue":"12","key":"10.1016\/j.ygyno.2020.11.035_bb0130","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"The Lancet Oncology."},{"key":"10.1016\/j.ygyno.2020.11.035_bb0135","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2020.11.035_bb0140","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","article-title":"Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182","volume":"33","author":"Horowitz","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.035_bb0145","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3390\/jcm9041235","article-title":"Rethinking radical surgery in interval Debulking surgery for advanced-stage ovarian cancer patients undergoing neoadjuvant chemotherapy","volume":"9","author":"Lee","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.035_bb0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10434-004-1167-z","article-title":"Long-term survival of peritoneal carcinomatosis of colorectal origin","volume":"12","author":"Verwaal","year":"2005","journal-title":"Ann. Surg. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2020.11.035_bb0155","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study","volume":"22","author":"Glehen","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2020.11.035_bb0160","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ejso.2007.12.003","article-title":"Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience","volume":"34","author":"Scaringi","year":"2008","journal-title":"Eur. J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.035_bb0165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejso.2017.11.003","article-title":"Prognostic value of peritoneal cancer index in primary advanced ovarian cancer","volume":"44","author":"Llueca","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.035_bb0170","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-018-0415-y","article-title":"A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: A two- centers experience","volume":"11","author":"Ghisoni","year":"2018","journal-title":"Journal of Ovarian Research"},{"issue":"6","key":"10.1016\/j.ygyno.2020.11.035_bb0175","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2017.28.e73","article-title":"External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"28","author":"Lee","year":"2017","journal-title":"J. Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.11.035_bb0180","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","article-title":"Assessment of a chemotherapy response score (CRS) system for Tubo-ovarian high-grade serous carcinoma (HGSC)","volume":"38","author":"Ditzel","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"9","key":"10.1016\/j.ygyno.2020.11.035_bb0185","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/IGC.0000000000001366","article-title":"Prognostic value of pathologic chemotherapy response score in patients with ovarian cancer after neoadjuvant chemotherapy","volume":"28","author":"Michaan","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"22","key":"10.1016\/j.ygyno.2020.11.035_bb0190","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.035_bb0195","doi-asserted-by":"crossref","first-page":"10936","DOI":"10.1038\/s41598-020-67823-8","article-title":"A priori prediction of tumour response to neoadjuvant chemotherapy in breast cancer patients using quantitative CT and machine learning","volume":"10","author":"Moghadas-Dastjerdi","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ygyno.2020.11.035_bb0200","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2018.29.e53","article-title":"Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study","volume":"29","author":"Ceresoli","year":"2018","journal-title":"J. Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2020.11.035_bb0205","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1245\/s10434-015-5069-z","article-title":"Surgical complexity impact on survival after complete cytoreductive surgery for advanced ovarian cancer","volume":"23","author":"Martinez","year":"2016","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.11.035_bb0210","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/AOG.0b013e3182475f8a","article-title":"Intraoperative hypothermia during cytoreductive surgery for ovarian cancer and perioperative morbidity","volume":"119","author":"Moslemi-Kebria","year":"2012","journal-title":"Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.11.035_bb0215","first-page":"9385","article-title":"Clinical significance of heat shock proteins in gastric cancer following hyperthermia stress: indications for hyperthermic intraperitoneal chemoperfusion therapy","volume":"15","author":"Tu","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ygyno.2020.11.035_bb0220","series-title":"Poster Presentations - Proffered Abstracts. Vol 26. American Association for Cancer Research","first-page":"B79","article-title":"Abstract B79: Effect of HIPEC on immune microenvironment in epithelial ovary cancer","author":"Rizwan","year":"2020"},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.035_bb0225","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2013.01.010","article-title":"Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study","volume":"129","author":"Argenta","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.035_bb0230","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/IGC.0000000000000664","article-title":"Heated IntraPEritoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review","volume":"26","author":"Hotouras","year":"2016","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820341639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820341639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:54:28Z","timestamp":1758772468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820341639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0090825820341639"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.11.035","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}